Suowen Xu

Aug 19, 2024 | biorxiv.org | Suowen Xu |Zhenghong Liu |Tian Tian |Wenqi Zhao

AbstractObesity is a debilitating disease with increasing worldwide prevalence. Despite its high prevalence, specific pharmacologic intervention for obesity is challenging. Here, we report that halofuginone, an FDA-approved anti-scleroderma and anti-protozoal drug, is a promising anti-obesity agent in rodent models.